Bajaj Healthcare has received approval from Central Drugs Standard Control Organisation (CDSCO) on December 31, 2025, to conduct Clinical Trial and Bioequivalence Study of Suvorexant Tablets.
Earlier, the company had received a positive recommendation from the Subject Expert Committee (Neurology & Psychiatry) of the CDSCO to initiate Phase III clinical trials for Suvorexant Tablets, available in strengths of 5mg, 10mg, 15mg, and 20mg.
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.
